Related Experiment Video

Updated: Feb 26, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Differential TBXA2 receptor transcript stability is dependent on the C924T polymorphism

Vincenzo De Iuliis1, Sebastiano Ursi1, Alfonso Pennelli2

  • 1SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy.

Prostaglandins & Other Lipid Mediators
|July 16, 2017
PubMed
Abstract

Insights

The TBXA2R TT genotype may protect against atherothrombosis by increasing transcript instability and reducing platelet aggregation, especially in aspirin-treated patients. This finding highlights the post-transcriptional role of the C924T polymorphism in cardiovascular health.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cardiovascular Research

Background:

  • Investigated the post-transcriptional role of the C924T polymorphism (rs4523) in the 3' region of the TBXA2R gene.
  • Aimed to better characterize molecular mechanisms involved in processing mutated transcripts.

Purpose of the Study:

  • To analyze the impact of the C924T polymorphism on TBXA2R mRNA stability and receptor expression.
  • To correlate these molecular changes with platelet aggregation and potential atherothrombotic risk.

Main Methods:

  • Dose-response experiments with Actinomycin D on MEG-01 cells to assess cell viability.
  • Quantitative real-time PCR (qRT-PCR) to analyze TBXA2R mRNA stability.
  • Analysis of TBXA2R expression levels and glycosylation in wild type (CC) versus mutant (TT) genotypes.
  • Assessment of platelet aggregation in relation to the C924T polymorphism.

Main Results:

  • Actinomycin D significantly decreased cell viability, with greater impact at higher concentrations and longer treatment durations.
  • TBXA2R mRNA stability was increased for the wild type (C) allele compared to the mutant (T) allele.
  • The wild type (CC) genotype showed higher TBXA2R expression (including glycosylated forms) compared to the mutant (TT) genotype.
  • Reduced platelet aggregation was observed in individuals with the TT genotype, irrespective of the aggregation stimulus.

Conclusions:

  • The TBXA2R TT genotype is associated with increased mRNA instability and reduced platelet aggregation.
  • These findings suggest a potential protective role of the TBXA2R TT genotype against atherothrombosis.
  • This protective effect may be particularly relevant in high-risk, aspirin-treated patients.
Keywords:
Gene expressionPlatelet aggregationSingle nucleotide polymorphism

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.6K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
158.2K
Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
19.6K